Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients with Risk Factors

Launched by HOSPICES CIVILS DE LYON · Aug 18, 2017

Keywords

ClinConnect Summary

The clinical trial, called the DROP Program, is studying how to improve the safety and effectiveness of oral anticancer drugs for patients with cancer who are receiving treatment at home. The trial recognizes that while more people are taking these oral medications, it can lead to problems like forgetting to take the medicine, managing side effects, or dealing with interactions with other medications. This is especially important for older patients who often take multiple medications for other health conditions. The aim of the DROP Program is to provide better support and monitoring for these patients to reduce the risks associated with their treatment.

To be eligible for this trial, participants must be at least 18 years old, have a cancer diagnosis, and be starting or changing their oral anticancer medication. They should also be able to manage their medications at home and be taking five or more drugs in total. Participants will receive additional care and support through the DROP Program, which may help ensure they take their medications correctly and manage any side effects. It's important to note that the trial is actively recruiting participants, and those interested should discuss it with their doctor to see if they qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient aged 18 years old or more
• • With cancer
• • For wich the initiation or change of an oral anticancer drug is prescribed
• • With life expectancy estimated to be 6 months or more, in the opinion of the investigator
• • Of which the treatment with oral anticancer medication is estimated to be 6 months or more in the opinion of the oncologist
• • Benefiting from an initiation or a change of oral anticancer agents according to the MA: cytotoxic agent, targeted therapy, hormonal therapy (excluding adjuvant treatments);
• • of which the oral anticancer drug is delivered in pharmacy of town or in retrocession hospital;
• • With ambulatory status (not hospitalized for the management and treatment )
• • Taking 5 or more drugs, including the oral anticancer treatment, and / or treated with an oral anticancer drug requiring complex regimen (combination of 2 oral anticancer drugs, or sequential rate of intake, or associated to intravenous chemotherapy)
• • With a sufficient autonomy for the management of medication at home
• • Without either cognitive disorders or major psychiatric disorders, in the opinion of the investigator
• • Ability to read, write and understand the French language
• • Having given his written consent to participate in the study
• • Patient affiliated to the social security scheme or equivalent
• Exclusion Criteria:
• • Pregnant or lactating woman
• • Patient on anti-PD1, anti-PDL-1 or anti-CTLA4-4 immunotherapy concomitant with oral anticancer treatment
• • Patient under radiotherapy concomitant treatment with oral anticancer
• • Oral anticancer agent prescribed in a delivery circuit as part of an ATU or clinical trial;
• • Patient with significant cognitive or psychiatric disorders, in the opinion of the investigator;
• • Management of drug treatment at home is performed exclusively by the caregiver;
• • Not having declared a doctor;
• • Not having a usual city pharmacy, or reporting 2 or more usual city pharmacies;
• • Patient who has already benefited from a therapeutic education program
• • In institution or guardianship, major protected by the Law.